modelCombinationsOfRauwolfiaA
Extends from Pharmacolibrary.Drugs.ATC.C.C02AA03.
Information
| name: | CombinationsOfRauwolfiaAlkaloids | |
| ATC code: | C02AA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 5 | L |
| clearance: | 0.07 | L/kg/h |
| other parameters in model implementation | ||
Combinations of rauwolfia alkaloids are antihypertensive agents containing mixtures of alkaloids derived from Rauwolfia serpentina, such as reserpine, deserpidine, and ajmaline. These drugs were commonly used in the mid-20th century for the management of essential hypertension, but their use has declined considerably due to the advent of safer and more effective antihypertensive agents. They are rarely used today in modern clinical practice.
Pharmacokinetics
No published population pharmacokinetic studies exist for combinations of rauwolfia alkaloids as a fixed mixture. Available data are based on estimated parameters of the principal alkaloid, reserpine, after oral administration in healthy adults.
References
Pétain, A, et al., & Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer chemotherapy and pharmacology 84(2) 373–382. DOI:10.1007/s00280-019-03872-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31134323
Balis, FM, et al., & Bleyer, WA (1998). Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 92(10) 3569–3577. PUBMED:https://pubmed.ncbi.nlm.nih.gov/9808549
Urien, S, et al., & Deporte-Fety, R (2003). Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer chemotherapy and pharmacology 52(2) 99–107. DOI:10.1007/s00280-003-0616-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12768319
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)